Trade this ETF at your broker
Index | ROBO Global Healthcare Technology and Innovation |
Investment focus | Equity, World, Health Care |
Fund size | EUR 62 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 18.98% |
Inception/ Listing Date | 2 July 2019 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | No ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
AxoGen | 3.12% |
CareDx | 2.59% |
Intuitive Surgical | 1.99% |
Veracyte | 1.98% |
Omnicell | 1.96% |
Illumina, Inc. | 1.88% |
EXACT Sciences | 1.84% |
Thermo Fisher Scientific, Inc. | 1.80% |
Koninklijke Philips NV | 1.78% |
Revvity | 1.78% |
United States | 78.13% |
Switzerland | 5.90% |
Japan | 2.39% |
Netherlands | 1.78% |
Other | 11.80% |
Health Care | 93.91% |
Technology | 1.55% |
Consumer Discretionary | 1.13% |
Other | 3.41% |
Broker | Rating | Execution fee | Account fee | |
---|---|---|---|---|
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.95€ 0.95% | 0.00€ |
Broker | Rating | Order fee | ETF savings plans | |
---|---|---|---|---|
0.99€ | 2534 | View offer* | ||
1.00€ | 2234 | View offer* | ||
0.00€ | 1402 | View offer* | ||
0.00€ | 1087 | View offer* | ||
0.00€ | 897 | View offer* |
YTD | +3.34% |
1 month | +0.65% |
3 months | +5.04% |
6 months | +3.83% |
1 year | +11.52% |
3 years | -30.51% |
5 years | +25.32% |
Since inception (MAX) | +24.31% |
2023 | -6.26% |
2022 | -29.18% |
2021 | +8.52% |
2020 | +51.67% |
Volatility 1 year | 18.98% |
Volatility 3 years | 24.78% |
Volatility 5 years | 25.48% |
Return per risk 1 year | 0.61 |
Return per risk 3 years | -0.46 |
Return per risk 5 years | 0.18 |
Maximum drawdown 1 year | -12.72% |
Maximum drawdown 3 years | -50.00% |
Maximum drawdown 5 years | -50.89% |
Maximum drawdown since inception | -50.89% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | XMLH | - - | - - | - |
Borsa Italiana | EUR | DOCT | DOCT IM DOCEURIV | DOCT.MI DOCTEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | DOCG | DOCG LN NA | DOCG.L NA | Flow Traders B.V. |
London Stock Exchange | USD | DOCT | DOCT LN NA | DOCT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | DOCT | DOCT SW DOCEURIV | DOCT.S | Flow Traders B.V. |
XETRA | EUR | XMLH | XMLH GY DOCEURIV | DOCT.DE | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,037 | 0.40% p.a. | Accumulating | Sampling |
L&G Pharma Breakthrough UCITS ETF | 16 | 0.49% p.a. | Accumulating | Full replication |
Harbor Health Care UCITS ETF Accumulating | 15 | 0.89% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 7 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |